Business
DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc.
DRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc. Cana...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n\n\nDRI Healthcare Trust Comments on Proposed Acquisition of KalVista Therapeutics, Inc.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCanada NewsWire\n\n\nTORONTO, April 29, 2026 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (\"DRI Healthcare\") today noted the announcement by KalVista Therapeutics, Inc. (\"KalVista\"), that it has entered into a definitive agreement to be acquired by Chiesi Group, an international research-focused biopharmaceutical group (the \"Transaction\").\n\n\n\n\n\n\n\nDRI Healthcare congratulates KalVista on the announced Transaction.As previously disclosed, DRI Healthcare is entitled to worldwide net sales of all formulations of Ekterly (sebetralstat) pursuant to a royalty agreement with KalVista. Based on publicly available information, the Transaction, if consummated, may constitute a change of control under DRI Healthcare's royalty agreement.DRI Healthcare is currently reviewing the announced Transaction and evaluating its rights and obligations under the royalty agreement, including a put option and buyback provisions that may become exercisable in connection with the Transaction. No determination has been made at this time with respect to any actions DRI Healthcare may take in connection with the Transaction.About DRI HealthcareDRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3.0 billion, acquiring more than 75 royalties on 50-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol \"DHT.UN\" and in U.S. dollars under the symbol \"DHT.U\". To learn more, visit drihealthcare.com or follow us on LinkedIn.Caution concerning forward-looking statementsThis news release may contain forward-looking information within the meaning of applicable securities legislation. Forward-looking information can generally be identified by the use of words such as \"expect\", \"continue\", \"anticipate\", \...